scholarly journals Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment

2020 ◽  
Vol 33 (2) ◽  
Author(s):  
Fathima F. Ismail ◽  
John May ◽  
John Moi ◽  
Rodney Sinclair
Keyword(s):  
Psoriatic Arthritis ◽  
Clinical Improvement ◽  
Psoriatic Nail Disease ◽  
Nail Disease

Psoriatic nail disease, a predictor of psoriatic arthritis

2014 ◽  
Vol 171 (5) ◽  
pp. 935-936 ◽  
Author(s):  
R. Baran ◽  
B. Sigurgeirsson
Keyword(s):  
Psoriatic Arthritis ◽  
Psoriatic Nail Disease ◽  
Nail Disease

scholarly journals 187 Improvement of psoriatic nail disease in psoriatic arthritis patients treated with adalimumab: results of an observational cohort up to 36 months

Rheumatology ◽  
2018 ◽  
Vol 57 (suppl_3) ◽  
Author(s):  
Neil McHugh ◽  
Charlotte Cavill ◽  
William Tillett ◽  
Eleanor Korendowych ◽  
Joseph Hickey ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Observational Cohort ◽  
Psoriatic Nail Disease ◽  
Nail Disease

scholarly journals AB0576 BONE EROSION IN PSORIATIC ARTHRITIS ASSOCIATED WITH PSORIASIS DURATION, SKIN, NAIL AND JOINT DISEASE SEVERITY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1325.2-1326
Author(s):  
M. Chamurlieva ◽  
E. Loginova ◽  
T. Korotaeva ◽  
Y. Korsakova ◽  
E. Gubar ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Psoriatic Arthritis ◽  
Disease Severity ◽  
Bone Erosion ◽  
Joint Disease ◽  
Practice Research ◽  
Forest Plot ◽  
Clinical Practice Research Datalink ◽  
Increased Risk ◽  
Nail Disease

Background:Psoriatic arthritis (PsA) is heterogeneous in its clinical presentation and disease course, but many patients (pts) develop a destructive form of arthritis. Psoriasis (PsO) precedes arthritis by an average of 7 years. [1]. Theory of transition from PsO to PsA has been proposed recently [2]. But association between skin disease severity and joint disease are still unclear.Objectives:to evaluate association between bone erosion, PsO duration, skin and nail disease severity in PsA pts based on data from clinical practice (RU-PsART cohort).Methods:737 (M/F=350/387) PsA pts fulfilling the CASPAR criteria were included. Mean age 47.4±12.7 years (yrs), PsA duration 55[17;120] mos., PsO duration 165[74.5;292] mos., mean DAPSA 23.3[14;36.9] mos., HAQ-DI - 0.98 [0.5;1.38], CRP - 7.4 [2.1;18] mg/l. All pts underwent standard clinical examination (tender joins count (TJC)/68, swelling joints count (SJC)/66, CRP (mg/l), DAPSA, dactylitis, enthesitis by LEI + Plantar Facia (PF), HAQ-DI. Mild disease was defined as body surface area (BSA)≤10%, moderate to severe as BSA>10%. The presence/absent of nail PsO was evaluated. X-ray of feet and hand were done in 622 out of 737 pts. The one-factor model of logistic regression was used to identify a group of features that are associated with achievement MDA. M±SD, Me [Q25; Q75], Min-Max, %, t-test, Pierson-χ2, Manna-Whitney tests, ORs with 95% CI were performed. All p<0.05 were considered to indicate statistical significance.Results:PsO precedes of PsA by an average of 9.2 years. BSA≤10% was found in 615 out of 672 pts (91.5%), BSA>10% - in 57 out of 672 pts (8.5%). Nail PsO were seen in 230 out of 737 (31.2%). Bone erosion was found in 237 out of 622 of pts (38.1%). Among these pts nail PsO were seen in 67 out of 237 pts (28.3%). Enthesitis found in 236 out of 737 pts (42.1%), dactylitis – in 197 out 731 pts (27%), axial PsA – in 315 out of 731 pts (43.1%). Bone erosion significantly associated with PsO duration more than 5 yrs., skin and nail PsO severity, high PsA activity by DAPSA, axial manifestation and duration of PsA > 36 mos. (Figure 1).Figure 1Forest plot of factors associated with bone erosion in PsA pts.Conclusion:In our cohort the majority of PsA pts had mild PsO preceded PsA on average of 9.2 yrs. Bone erosion was found in 30% of PsA pts which associated with PsO duration, skin and nail disease severity as well as with PsA activity. Early diagnosis and therapeutic intervention within a “window of opportunity” are very important for improving outcomes and prevent structural damage in PsA.References:[1]Tillett W, et al. Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. Rheumatol. 2017; 56, 2109–2113[2]Scher JU, et al. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153-166. doi: 10.1038/s41584-019-0175-0. PMID: 30742092.Disclosure of Interests:None declared.

scholarly journals Imaging of psoriatic nail disease pre and post anti-TNF therapy shows persistent subclinical inflammation despite good clinical response

2013 ◽  
Vol 14 (S1) ◽  
Author(s):  
Zoe Ash ◽  
Richard Hodgson ◽  
Andrew Grainger ◽  
Sibel Z Aydin ◽  
Concepcion Castillo-Gallego ◽  
...  
Keyword(s):  
Clinical Response ◽  
Subclinical Inflammation ◽  
Good Clinical Response ◽  
Psoriatic Nail Disease ◽  
Nail Disease

scholarly journals The use of ultrasonography in the diagnosis of nail disease among patients with psoriasis and psoriatic arthritis: a systematic review

2019 ◽  
Vol 59 (1) ◽  
Author(s):  
José Alexandre Mendonça ◽  
Sibel Zehra Aydin ◽  
Maria-Antonietta D’Agostino
Keyword(s):  
Systematic Review ◽  
Psoriatic Arthritis ◽  
Nail Disease

Composite Measures in Psoriatic Arthritis: GRAPPA 2008

2010 ◽  
Vol 37 (2) ◽  
pp. 453-461 ◽  
Author(s):  
DAFNA D. GLADMAN ◽  
ROBERT LANDEWÉ ◽  
NEIL J. McHUGH ◽  
OLIVER FITZGERALD ◽  
DIAMANT THACI ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Lupus Erythematosus ◽  
Current Status ◽  
Composite Measure ◽  
Psoriatic Disease ◽  
Composite Measures ◽  
Composite Methods ◽  
Nail Disease ◽  
Considerable Discussion ◽  
Assessment Of Disease Activity

At the 2008 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) in Leeds, UK, members discussed the value and current status of composite measures for the assessment of psoriatic arthritis (PsA). In plenary presentations, examples of composite measures developed for rheumatoid arthritis (RA) and ankylosing spondylitis (AS) were reviewed, followed by a presentation of the assessment of disease activity in systemic lupus erythematosus. Three recently devised composite methods of assessing activity or response in PsA also were presented. Considerable discussion followed in breakout groups, and members agreed that a new composite measure specifically for PsA is necessary. The composite measure should include components that encompass the spectrum of psoriatic disease, i.e., in addition to assessment of peripheral joints, it should include assessment of sacroiliitis, spondylitis, enthesitis, and dactylitis, as well as skin and nail disease.

Evaluation and Treatment of Nail Disease in Patients with Psoriatic Arthritis

2012 ◽  
Author(s):  
Luigi Scarpato ◽  
Luisa Costa ◽  
Maria Maddalena Aquino ◽  
Raffale Scarpa
Keyword(s):  
Psoriatic Arthritis ◽  
Nail Disease

Alefacept treatment of psoriatic nail disease: How severe should nail psoriasis be?

2006 ◽  
Vol 54 (4) ◽  
pp. 742-743 ◽  
Author(s):  
John E.M. Körver ◽  
Peter C.M. van de Kerkhof ◽  
Marcel C. Pasch
Keyword(s):  
Nail Psoriasis ◽  
Psoriatic Nail Disease ◽  
Nail Disease

Psoriatic Nail Disease: Quality of Life and Treatment

2009 ◽  
Vol 13 (5_suppl) ◽  
pp. S102-S106 ◽  
Author(s):  
Aditya K. Gupta ◽  
Elizabeth A. Cooper
Keyword(s):  
Quality Of Life ◽  
Psoriatic Arthritis ◽  
Plaque Psoriasis ◽  
Large Scale ◽  
Severity Index ◽  
Biologic Therapies ◽  
Nail Psoriasis ◽  
Psoriatic Nail Disease

Nail psoriasis is common among patients with plaque psoriasis or psoriatic arthritis and has a detrimental effect on quality of life. However, there are currently no standardized therapeutic regimens for nail psoriasis. Traditional treatments for nail psoriasis, which include topical, intralesional, and oral therapies, may be time-consuming, painful, or unsafe when administered long term. Biologic therapies have demonstrated efficacy for plaque psoriasis and psoriatic arthritis; these therapies may be particularly promising for the treatment of nail psoriasis as both groups of patients have an elevated incidence of nail dystrophy. The biologic therapies adalimumab, alefacept, efalizumab, etanercept, and infliximab have demonstrated clinically important nail psoriasis improvements using the Nail Psoriasis Severity Index, a helpful tool that, upon validation, will allow comparison across treatments and trials. Large-scale, long-term trials using standardized outcome measures are needed to further evaluate biologic therapies for the treatment of nail psoriasis.

Sign in / Sign up

Export Citation Format

Share Document